Ensysce Biosciences Inc. (ENSC)
6.88
-0.29 (-4.04%)
At close: Jan 14, 2025, 3:59 PM
6.70
-2.62%
After-hours Jan 14, 2025, 04:40 PM EST
undefined% (undefined)
| Bid | 6.01 |
| Market Cap | 8.98M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -29.1 |
| PE Ratio (ttm) | -0.24 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 7.33 |
| Volume | 50,479 |
| Avg. Volume (20D) | 1,916,693 |
| Open | 7.06 |
| Previous Close | 7.17 |
| Day's Range | 6.76 - 7.14 |
| 52-Week Range | 2.12 - 30.90 |
| Beta | undefined |
About ENSC
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 14, 2018
Employees 7
Stock Exchange NASDAQ
Ticker Symbol ENSC
Website https://www.ensysce.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ENSC stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Ensysce Biosciences Inc. is scheduled to release its earnings on Mar 14, 2025,
before market opens.
Analysts project revenue of $245.00K, reflecting a -52.43% YoY shrinking and earnings per share of -1.95, making a -88.50% decrease YoY.
Analysts project revenue of $245.00K, reflecting a -52.43% YoY shrinking and earnings per share of -1.95, making a -88.50% decrease YoY.
1 month ago ·
Source
+14.48%
Ensysce Biosciences shares are trading higher afte...
Unlock content with
Pro Subscription
2 months ago ·
Source
+5.14%
Ensysce Biosciences shares are trading higher after the company reported better-than-expected Q3 financial results.
